MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
The ATAI Life Sciences IPO could come as soon as the end of January. What does this mean for psychedelic stock investors?
Colorado’s governor is looking to further assist the marijuana industry and entrepreneurs from communities most impacted by the drug war through a proposed program to provide businesses a pool of resources that they are currently ineligible for.
PALM BEACH, Fla., Jan. 6, 2021 /PRNewswire/ -- In the few places where cannabis is legal, it can be incredibly lucrative. In 2019, the nascent worldwide cannabis sector pumped out approximately $15 billion in sales.
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Health"), a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders.
Numinus announces a product development agreement with Optimi Health Corp.